Update: Wuxi Biologics Among 33 Chinese Firms to Land on Market-Rattling U.S. Government List

By Hua Ang, Zhang Erchi and Flynn Murphy

Bioreactors at Wuxi Biologics’s research and development laboratory in Shanghai. Photo: Bloomberg

The U.S. Department of Commerce listed 33 Chinese entities it said use American export items in ways that it has been unable to trace, injecting fresh volatility into markets.

The most high-profile among them was Chinese novel drugmaker Wuxi Biologics Cayman Inc., which suspended trading in Hong Kong after its addition to the department’s unverified list sparked a record sell-off.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS